GT Biopharma Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update
Presented novel TriKE® pre-clinical data driving NK cell immunotherapy against non-small cell lung cancer (NSCLC) in the hypoxic solid tumor microenvironment...